Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Metastasis | Research

Differential expression of PLAC1 and Netrin-1 in liver metastasis of colorectal cancer and its predictive value

Authors: Zhijun Wang, Lei Deng, Xiwen Xu, Lianwu Zhao

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Objective

To explore the differential expression of placental specific gene 1 (PLAC1) and neurite guidance factor 1 (netrin-1) in colorectal cancer (CRC) liver metastasis and its predictive value.

Methods

Paraffin specimens of primary CRC were selected, including 60 simple colorectal cancer specimens and 47 liver metastasis specimens. At the same time, 40 cases of normal colorectal mucosa were taken as the control group. The expression of PLAC1 and Netrin-1 in tissue was detected by immunohistochemistry (IHC). The correlation between PLAC1 and Netrin-1 expression and clinicopathological characteristics of patients with CRC liver metastases was analyzed. Logistic analysis was adopted to analyze the influencing factors of liver metastasis in CRC. A prediction model was established and ROC curve was used to detect the discrimination of the prediction model. The clinical value of PLAC1 and netrin-1 in predicting liver metastasis of CRC was analyzed using ROC curve. The relationship between the expression of PLAC1 and netrin-1 and the prognosis of CRC patients with liver metastasis was analyzed using Kaplan Meier survival curve.

Results

The positive staining of PLAC1 and netrin-1 was mainly located in the cytoplasm by IHC detection. Positive expression of PLAC1 and netrin-1 in CRC tissues was markedly higher than that in normal colorectal mucosal epithelium (P < 0.05). Positive expression of PLAC1 in metastatic group was higher than that in non-metastatic group without significant difference (P > 0.05). The metastasis group had much higher positive expression of netrin-1 than the non-metastasis group (P < 0.05). The content of PLAC1 in the tissues of CRC with liver metastasis had a close relationship with differentiation degree and lymph node metastasis (P < 0.05). The expression of Netrin-1 in the tissues of CRC with liver metastasis was associated with Dukes stage, differentiation degree and lymph node metastasis (P < 0.05). Logistic regression analysis showed that Dukes stage, differentiation, lymph node metastasis, CEA, Alb and D-dimer were the independent risk factors for liver metastasis of CRC (P < 0.05). The model was constructed according to the regression coefficients and constant terms, and the discrimination of the prediction model was evaluated using ROC curve, with the AUC of 0.903 (95% CI 0.831 ~ 0.975), the sensitivity of 93.80%, the specificity of 80.00%, and the Jordan index of 0.738. The AUC of PLAC1 and netrin-1 alone and combined detection to predict liver metastasis of CRC were 0.805, 0.793 and 0.921, respectively. The survival time of patients with positive PLAC1 and netrin-1 expression were sharply shorter than that of the patients with negative expression (P < 0.05).

Conclusions

The expression of PLAC1 and netrin-1 was strongly increased in CRC with liver metastasis, which had a certain clinical value in predicting liver metastasis of CRC. Dukes stage, differentiation degree, lymph node metastasis, CEA, Alb and D-dimer were independent risk factors for liver metastasis of CRC, and the model based on these indicators had good discrimination for effectively evaluating the risk of liver metastasis in CRC.
Literature
1.
go back to reference Garcia RM, Dwyer AJ, Worrall S, et al. The current landscape of research advocacy and education for patients with colorectal cancer. Curr Treat Options Oncol. 2022;23(5):645–57.CrossRefPubMed Garcia RM, Dwyer AJ, Worrall S, et al. The current landscape of research advocacy and education for patients with colorectal cancer. Curr Treat Options Oncol. 2022;23(5):645–57.CrossRefPubMed
2.
go back to reference Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–47.CrossRefPubMed Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–47.CrossRefPubMed
3.
go back to reference Rada M, Lazaris A, Kapelanski-Lamoureux A, Mayer TZ, Metrakos P. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: a theoretical model. Semin Cancer Biol. 2021;71:52–64.CrossRefPubMed Rada M, Lazaris A, Kapelanski-Lamoureux A, Mayer TZ, Metrakos P. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: a theoretical model. Semin Cancer Biol. 2021;71:52–64.CrossRefPubMed
4.
go back to reference Lin C, Qian P, Zhang Y, et al. Plac1 promotes nasopharyngeal carcinoma cells proliferation, migration and invasion via Furin/NICD/PTEN pathway. Tissue Cell. 2021;69:101480.CrossRefPubMed Lin C, Qian P, Zhang Y, et al. Plac1 promotes nasopharyngeal carcinoma cells proliferation, migration and invasion via Furin/NICD/PTEN pathway. Tissue Cell. 2021;69:101480.CrossRefPubMed
5.
go back to reference Chen R, Sheng C, Ma R, et al. PLAC1 is an independent predictor of poor survival, and promotes cell proliferation and invasion in cervical cancer. Mol Med Rep. 2021;24(5):800.CrossRefPubMedPubMedCentral Chen R, Sheng C, Ma R, et al. PLAC1 is an independent predictor of poor survival, and promotes cell proliferation and invasion in cervical cancer. Mol Med Rep. 2021;24(5):800.CrossRefPubMedPubMedCentral
6.
go back to reference Yu Y, Xu Y, Cai W, et al. Expression level of PLAC1 in osteosarcoma patients and its regulatory effect on the development of osteosarcoma. J BUON. 2021;26(2):592–8.PubMed Yu Y, Xu Y, Cai W, et al. Expression level of PLAC1 in osteosarcoma patients and its regulatory effect on the development of osteosarcoma. J BUON. 2021;26(2):592–8.PubMed
7.
go back to reference Sung PJ, Rama N, Imbach J, et al. Cancer-associated fibroblasts produce Netrin-1 to control cancer cell plasticity. Cancer Res. 2019;79(14):3651–61.CrossRefPubMed Sung PJ, Rama N, Imbach J, et al. Cancer-associated fibroblasts produce Netrin-1 to control cancer cell plasticity. Cancer Res. 2019;79(14):3651–61.CrossRefPubMed
8.
go back to reference Villanueva AA, Sanchez-Gomez P, Muñoz-Palma E, et al. The netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin-β1 and focal adhesion kinase activation. Cell Adh Migr. 2021;15(1):58–73.CrossRefPubMedPubMedCentral Villanueva AA, Sanchez-Gomez P, Muñoz-Palma E, et al. The netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin-β1 and focal adhesion kinase activation. Cell Adh Migr. 2021;15(1):58–73.CrossRefPubMedPubMedCentral
9.
go back to reference El-Gamal R, Mokhtar N, Ali-El-Dein B, et al. Netrin-1: a new promising diagnostic marker for muscle invasion in bladder cancer. Urol Oncol. 2020;38(7):640e1–12.CrossRef El-Gamal R, Mokhtar N, Ali-El-Dein B, et al. Netrin-1: a new promising diagnostic marker for muscle invasion in bladder cancer. Urol Oncol. 2020;38(7):640e1–12.CrossRef
10.
go back to reference Buccafusca G, Proserpio I, Tralongo AC, et al. Early colorectal cancer: diagnosis, treatment and survivorship care. Crit Rev Oncol Hematol. 2019;136:20–30.CrossRefPubMed Buccafusca G, Proserpio I, Tralongo AC, et al. Early colorectal cancer: diagnosis, treatment and survivorship care. Crit Rev Oncol Hematol. 2019;136:20–30.CrossRefPubMed
11.
go back to reference Phelip JM, Tougeron D, Léonard D, et al. Metastatic colorectal cancer (mCRC): french intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51(10):1357–63.CrossRefPubMed Phelip JM, Tougeron D, Léonard D, et al. Metastatic colorectal cancer (mCRC): french intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51(10):1357–63.CrossRefPubMed
12.
go back to reference Del Piccolo N, Shirure VS, Bi Y, et al. Tumor-on-chip modeling of organ-specific cancer and metastasis. Adv Drug Deliv Rev. 2021;175:113798.CrossRefPubMed Del Piccolo N, Shirure VS, Bi Y, et al. Tumor-on-chip modeling of organ-specific cancer and metastasis. Adv Drug Deliv Rev. 2021;175:113798.CrossRefPubMed
13.
go back to reference Mahmoudi AR, Ghods R, Rakhshan A, et al. Discovery of a potential biomarker for immunotherapy of melanoma: PLAC1 as an emerging target. Immunopharmacol Immunotoxicol. 2020;42(6):604–13.CrossRefPubMed Mahmoudi AR, Ghods R, Rakhshan A, et al. Discovery of a potential biomarker for immunotherapy of melanoma: PLAC1 as an emerging target. Immunopharmacol Immunotoxicol. 2020;42(6):604–13.CrossRefPubMed
15.
go back to reference Bo Z, Fang C, Deng D, et al. Research progress on common adverse events caused by targeted therapy for colorectal cancer (review). Oncol Lett. 2018;16(1):27–33. Bo Z, Fang C, Deng D, et al. Research progress on common adverse events caused by targeted therapy for colorectal cancer (review). Oncol Lett. 2018;16(1):27–33.
16.
go back to reference Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998–1009.CrossRefPubMed Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998–1009.CrossRefPubMed
17.
go back to reference Mahmoudian J, Ghods R, Nazari M, et al. PLAC1: biology and potential application in cancer immunotherapy. Cancer Immunol Immunother. 2019;68(7):1039–58.CrossRefPubMed Mahmoudian J, Ghods R, Nazari M, et al. PLAC1: biology and potential application in cancer immunotherapy. Cancer Immunol Immunother. 2019;68(7):1039–58.CrossRefPubMed
18.
go back to reference Nejadmoghaddam MR, Zarnani AH, Ghahremanzadeh R, et al. Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy. Rep. 2017;16(1):249–65. Nejadmoghaddam MR, Zarnani AH, Ghahremanzadeh R, et al. Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy. Rep. 2017;16(1):249–65.
19.
go back to reference Ren Y, Lv Y, Li T, et al. High expression of PLAC1 in colon cancer as a predictor of poor prognosis: a study based on TCGA data. Gene. 2020;763(1):145072.CrossRefPubMed Ren Y, Lv Y, Li T, et al. High expression of PLAC1 in colon cancer as a predictor of poor prognosis: a study based on TCGA data. Gene. 2020;763(1):145072.CrossRefPubMed
20.
go back to reference Li B, Shen K, Zhang J, et al. Serum netrin-1 as a biomarker for colorectal cancer detection. Cancer Biomark. 2020;28(3):391–6.CrossRefPubMed Li B, Shen K, Zhang J, et al. Serum netrin-1 as a biomarker for colorectal cancer detection. Cancer Biomark. 2020;28(3):391–6.CrossRefPubMed
21.
go back to reference Liu F, Zhang H, Shen D, et al. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1. J Gastroenterol. 2014;49(3):419–26.CrossRefPubMed Liu F, Zhang H, Shen D, et al. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1. J Gastroenterol. 2014;49(3):419–26.CrossRefPubMed
22.
go back to reference Nakayama H, Ohnuki H, Nakahara M, et al. Inactivation of axon guidance molecule netrin-1 in human colorectal cancer by an epigenetic mechanism. Biochem Biophys Res Commun. 2022;611:146–50.CrossRefPubMedPubMedCentral Nakayama H, Ohnuki H, Nakahara M, et al. Inactivation of axon guidance molecule netrin-1 in human colorectal cancer by an epigenetic mechanism. Biochem Biophys Res Commun. 2022;611:146–50.CrossRefPubMedPubMedCentral
23.
go back to reference Kefeli U, Ucuncu Kefeli A, Cabuk D, et al. Netrin-1 in cancer: potential biomarker and therapeutic target? Tumour Biol. 2017;39(4):1010428317698388.CrossRefPubMed Kefeli U, Ucuncu Kefeli A, Cabuk D, et al. Netrin-1 in cancer: potential biomarker and therapeutic target? Tumour Biol. 2017;39(4):1010428317698388.CrossRefPubMed
24.
25.
go back to reference Hu S, Li S, Teng D, et al. Analysis of risk factors and prognosis of 253 lymph node metastasis in colorectal cancer patients. BMC Surg. 2021;21(1):280–0.CrossRefPubMedPubMedCentral Hu S, Li S, Teng D, et al. Analysis of risk factors and prognosis of 253 lymph node metastasis in colorectal cancer patients. BMC Surg. 2021;21(1):280–0.CrossRefPubMedPubMedCentral
26.
go back to reference Campos-da-Paz M, Dórea JG, Galdino AS, et al. Carcinoembryonic antigen (CEA) and hepatic metastasis in colorectal cancer: update on biomarker for clinical and biotechnological approaches. Recent Pat Biotechnol. 2018;12(4):269–79.CrossRefPubMed Campos-da-Paz M, Dórea JG, Galdino AS, et al. Carcinoembryonic antigen (CEA) and hepatic metastasis in colorectal cancer: update on biomarker for clinical and biotechnological approaches. Recent Pat Biotechnol. 2018;12(4):269–79.CrossRefPubMed
27.
go back to reference China L, Freemantle N, Forrest E, et al. ATTIRE trial investigators. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808–17.CrossRefPubMed China L, Freemantle N, Forrest E, et al. ATTIRE trial investigators. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808–17.CrossRefPubMed
28.
go back to reference Liu C, Ning Y, Chen X, et al. D-Dimer level was associated with prognosis in metastatic colorectal cancer: a chinese patients based cohort study. Med (Baltim). 2020;99(7):e19243.CrossRef Liu C, Ning Y, Chen X, et al. D-Dimer level was associated with prognosis in metastatic colorectal cancer: a chinese patients based cohort study. Med (Baltim). 2020;99(7):e19243.CrossRef
29.
go back to reference Liu FF, Shen DH, Wang S, et al. [Expression of PLAC1/CP1 genes in primary colorectal carcinoma and its clinical significance]. Zhonghua Bing Li Xue Za Zhi. 2010;39(12):810–3.PubMed Liu FF, Shen DH, Wang S, et al. [Expression of PLAC1/CP1 genes in primary colorectal carcinoma and its clinical significance]. Zhonghua Bing Li Xue Za Zhi. 2010;39(12):810–3.PubMed
30.
go back to reference Ko SY, Dass CR, Nurgali K. Netrin-1 in the developing enteric nervous system and colorectal cancer. Trends Mol Med. 2012;18(9):544–54.CrossRefPubMed Ko SY, Dass CR, Nurgali K. Netrin-1 in the developing enteric nervous system and colorectal cancer. Trends Mol Med. 2012;18(9):544–54.CrossRefPubMed
Metadata
Title
Differential expression of PLAC1 and Netrin-1 in liver metastasis of colorectal cancer and its predictive value
Authors
Zhijun Wang
Lei Deng
Xiwen Xu
Lianwu Zhao
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Metastasis
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02908-y

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.